Citius Pharmaceuticals, Inc. (CTXR) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2025. Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on oncology, anti-infectives, and stem cell therapies. The company operates through wholly-owned subsidiary Leonard-Meron Biosciences, Inc. (LMB) and majority-owned subsidiaries Citius Oncology, Inc. (CTOR, 92.3% owned) and NoveCite, Inc. (75% owned). The company has generated no operating revenue to date and is currently in the pre-commercialization phase for its primary product candidate, LYMPHIR.
Key Financial Metrics
| Metric | Six Months Ended March 31, 2025 | Six Months Ended March 31, 2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(21,792,751) | $(17,775,339) |
| Net Loss Per Share (Basic & Diluted) | $(2.58) | $(2.79) |
| Operating Expenses | $21,300,292 | $20,311,024 |
| Cash and Cash Equivalents (End of Period) | $26,410 | $12,559,607 |
| Net Cash Used in Operating Activities | $(9,265,328) | $(13,921,321) |
| Net Cash Provided by Financing Activities | $6,039,858 | $0 |
| Total Assets | $121,481,411 | $116,651,751 |
| Total Liabilities | $57,905,619 | $42,549,921 |
| Working Capital | $(31,502,188) | $(21,594,157) |
Note: Working Capital calculated as Total Current Assets ($18,374,454) minus Total Current Liabilities ($49,876,642).
Material Changes vs. Prior Period
- Liquidity Crisis: Cash and cash equivalents plummeted from $3.25 million at September 30, 2024, to $26,410 at March 31, 2025. The company burned approximately $3.2 million in cash during the six-month period.
- Inventory Build-up: Inventory increased significantly to $15.3 million (from $8.3 million), driven by manufacturing of LYMPHIR commercial products in anticipation of sales.
- Liabilities: Current liabilities rose to $49.9 million, primarily due to accrued expenses ($8.8 million) and a $28.4 million license payable related to LYMPHIR milestones.
- Operating Expenses: Total operating expenses increased by approximately $1 million year-over-year, driven by a $2.2 million increase in General and Administrative (G&A) expenses related to pre-launch commercial activities for LYMPHIR.
- One-Time Gain Absence: The prior year period included a $2.4 million gain from the sale of New Jersey net operating losses, which did not recur in the current period.
Outlook, Risks, and Management Commentary
- Going Concern Warning: The company's independent auditors have issued a report stating there is substantial doubt about the company's ability to continue as a going concern. Management estimates that current cash resources, combined with $1.735 million in proceeds from an April 2, 2025 offering, will only fund operations through May 2025.
- Capital Needs: The company is actively engaged in capital raise initiatives to extend its runway. Failure to raise additional capital or generate revenue from LYMPHIR could result in dissolution or liquidation.
- Significant Obligations: The company faces substantial near-term cash outflows, including:
- Approximately $22.5 million in milestone payments due to Dr. Reddy's (partially deferred).
- Approximately $7.1 million in milestone payments due to Eisai (payment schedule agreed through December 2025).
- Minimum purchase commitments of approximately $17.3 million for drug substance manufacturing and $4.5 million for packaging through 2026.
- Product Status: LYMPHIR received FDA approval in August 2024. Mino-Lok Phase 3 trials are complete, with FDA guidance received for a future NDA submission. No revenue has been recognized from product sales to date.
- Stock Structure: A 1-for-25 reverse stock split was effective November 25, 2024. On April 17, 2025, the CEO purchased a share of Series A Preferred Stock with 1 billion votes to facilitate a potential increase in authorized common stock.
Investor Verification Checklist
- Cash Runway: Verify the status of capital raise efforts post-May 2025, given the current cash balance of $26,410.
- Debt and Milestones: Confirm the payment schedule and funding source for the $22.5 million Dr. Reddy's milestone and the $7.1 million Eisai obligation.
- Commercialization: Monitor the timeline for the first commercial sale of LYMPHIR to trigger revenue recognition and amortization of the $92.8 million in-process R&D asset.
- Equity Dilution: Review the impact of recent registered direct offerings (Nov 2024, Jan 2025, April 2025) and outstanding warrants (4.25 million shares) on shareholder dilution.
- Going Concern Status: Assess the risk of liquidation if financing is not secured immediately.